Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 30Breast Neoplasms 29Glioblastoma 23Multiple Myeloma 21Glioma 20Lymphoma 19Pancreatic Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 16Brain Neoplasms 14Sarcoma 13Squamous Cell Carcinoma of Head and Neck 12Rectal Neoplasms 11Neoplasm Metastasis 11Melanoma 11Lymphoma, Non-Hodgkin 11Thyroid Neoplasms 10Ovarian Neoplasms 10Oropharyngeal Neoplasms 10Neuroblastoma 9Mouth Neoplasms 9Medulloblastoma 9Lymphoma, Follicular 9Ependymoma 9Colorectal Neoplasms 9Central Nervous System Neoplasms 9Astrocytoma 9

Interventions

prednylidene 1deltacortene 1apalutamide 1Prednisone 1Magnetic Resonance Spectroscopy 1Gonadotropin-Releasing Hormone 1BAY 86-7548 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Stage II Prostate Adenocarcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT03113617 2023-12-12

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Stanford University

Phase 2 Completed
44 enrolled 8 charts
Genitourinary

Stage II Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡